Research programme: estrogen-related receptor alpha modulators - Galapagos

Drug Profile

Research programme: estrogen-related receptor alpha modulators - Galapagos

Alternative Names: ERR1 - Galapagos

Latest Information Update: 28 Oct 2010

Price : $50

At a glance

  • Originator ProStrakan
  • Class
  • Mechanism of Action ERRalpha estrogen-related receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 28 Oct 2010 Discontinued - Preclinical for Osteoporosis in France (unspecified route)
  • 22 Dec 2006 Galapagos NV acquires ProStrakan's drug discovery unit
  • 27 May 2005 Preclinical trials in Osteoporosis in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top